A Comparison of Vancomycin and Metronidazole for the Treatment of Clostridium difficile-associated Diarrhea (CDAD) in Medical Intensive Care Unit (MICU) |
Cho, Eun Ae
(Department of Pharmacy, Yonsei University Health System)
Lee, Kyung A (Department of Pharmacy, Yonsei University Health System) Kim, Jae Song (Department of Pharmacy, Yonsei University Health System) Kim, Soo Hyun (Department of Pharmacy, Yonsei University Health System) Son, Eun Sun (Department of Pharmacy, Yonsei University Health System) |
1 | Larson H.E., Price A.B., Honour P. et al. Clostridium difficile and the etiology of pseudomembranous colitis. The Lancet 1978;311(8073):1063-1066. DOI |
2 | Bartlett J.G. Clostridium difficile: clinical considerations. Rev Infect Dis 1990;12(Suppl 2):S243-51. DOI |
3 | Kelly C.P., Pothoulakis C. and LaMont J.T. Clostridium difficile colitis. N Engl J Med 1994;330(4):257-62. DOI |
4 | Monaghan T., Boswell T. and Mahida Y.R. Recent advances in clostridium difficile- associated disease. Gut 2008;57(6):850-60. |
5 | Teasley D.G., Gerding D.N., Olson M.M. et al. Prospective randomised trial of metronidazole 1983;2(8358):1043-46. |
6 | Cohen S.H., Gerding D.N., Johnson S. et al. Clinical practice guidelines for clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31(5):431-55. DOI |
7 | Kelly C.P., LaMont J.T. Clostridium difficile-more difficult than ever. N Engl J Med 2008;359(18):1932-40. DOI |
8 | Bartlett J.G. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002;346(5):334-39. DOI |
9 | Wenisch C., Parschalk B., Hasenhundl M. et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of clostridium difficile-associated diarrhea. Clin Infect Dis 1996;22(5):813-18. DOI |
10 | Musher D.M., Aslam S., Logan N. et al. Relatively poor outcome after treatment of clostridium difficile colitis with metronidazole. Clin Infect Dis 2005;40(11):1586-90. DOI |
11 | Pepin J., Alary M.E., Valiquette L. et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005;40(11):1591-97. DOI |
12 | Aslam S., Hamill R.J. and Musher D.M. Treatment of clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005;5(9):549-57. DOI |
13 | Al-Nassir W.N., Sethi A.K., Nerandzic M.M. et al. Comparison of clinical and microbiological response to treatment of clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008;47(1):56-62. DOI |
14 | Zar F.A., Bakkanagari S.R., Moorthi K.M. et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45(3):302-7. DOI |
15 | Hookman P., Barkin J.S. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol 2009;15(13):1554-80. DOI |
16 | Yoo-jung Choi Y.-s.C., Hye-sook Lee, Hyang-sook Kim et al. Evaluation of oral vancomycin use for the treatment of clostridium difficile-associated disease and risk factor analysis of treatment failure. J. Kor. Soc. Health-Syst. Pharm 2013;30(3):194-201. |
17 | Korea pharmaceutical information Center. Drug information. Available from http://drug.mfds.go.kr/html.indes.jsp. Accessed March 23, 2017. |
18 | Korea pharmaceutical information Center. Drug information. Available from http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199801540. Accessed March 23, 2017. |
19 | Clements A.C., Magalhaes R.J., Tatem A.J. et al. Clostridium difficile PCR ribotype 027:assessing the risks of further worldwide spread. Lancet Infect Dis 2010;10(6):395-404. DOI |
20 | Lee Y.J., Choi M.G., Lim C.H. et al. Change of clostridium difficile colitis during recent 10 years in Korea. Korean J Gastroenterol 2010;55(3):169-74. DOI |
21 | Loo V.G., Poirier L., Miller M.A. et al. A predominantly clonal multiinstitutional outbreak of clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353(23):2442-449. DOI |
22 | Yip C., Loeb M., Salama S. et al. Quinolone use as a risk factor for nosocomial clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol 2001;22(9):572-75. DOI |